{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:51Z","timestamp":1781835171807,"version":"3.54.5"},"reference-count":153,"publisher":"National Institute for Health and Care Research","issue":"31","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR127357"],"award-info":[{"award-number":["NIHR127357"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>Newly diagnosed open-angle glaucoma (OAG) and ocular hypertension (OHT) are habitually treated with intraocular pressure (IOP)-lowering eyedrops. Selective laser trabeculoplasty (SLT) is a safe alternative to drops and is rarely used as first-line treatment.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To compare health-related quality of life (HRQoL) in newly diagnosed, treatment-naive patients with OAG or OHT, treated with two treatment pathways: topical IOP-lowering medication from the outset (Medicine-1st) or primary SLT followed by topical medications as required (Laser-1st). We also compared the clinical effectiveness and cost-effectiveness of the two pathways.<\/jats:p><\/jats:sec>Design<\/jats:title>A 36-month pragmatic, unmasked, multicentre randomised controlled trial.<\/jats:p><\/jats:sec>Settings<\/jats:title>Six collaborating specialist glaucoma clinics across the UK.<\/jats:p><\/jats:sec>Participants<\/jats:title>Newly diagnosed patients with OAG or OHT in one or both eyes who were aged \u2265\u200918 years and able to provide informed consent and read and understand English. Patients needed to qualify for treatment, be able to perform a reliable visual field (VF) test and have visual acuity of at least 6 out of 36 in the study eye. Patients with VF loss mean deviation worse than \u201312\u2009dB in the better eye or \u201315\u2009dB in the worse eye were excluded. Patients were also excluded if they had congenital, early childhood or secondary glaucoma or ocular comorbidities; if they had any previous ocular surgery except phacoemulsification, at least 1 year prior to recruitment or any active treatment for ophthalmic conditions; if they were pregnant; or if they were unable to use topical medical therapy or had contraindications to SLT.<\/jats:p><\/jats:sec>Interventions<\/jats:title>SLT according to a predefined protocol compared with IOP-lowering eyedrops, as per national guidelines.<\/jats:p><\/jats:sec>Main outcome measures<\/jats:title>The primary outcome was HRQoL at 3 years [as measured using the EuroQol-5 Dimensions, five-level version (EQ-5D-5L) questionnaire]. Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness and safety.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 718 patients enrolled, 356 were randomised to Laser-1st (initial SLT followed by routine medical treatment) and 362 to Medicine-1st (routine medical treatment only). A total of 652 (91%) patients returned the primary outcome questionnaire at 36 months. The EQ-5D-5L score was not significantly different between the two arms [adjusted mean difference (Laser-1st\u2009\u2013\u2009Medicine-1st) 0.01, 95% confidence interval (CI) \u20130.01 to 0.03;p<\/jats:italic>\u2009=\u20090.23] at 36 months. Over 36 months, the proportion of visits at which IOP was within the target range was higher in the Laser-1st arm (93.0%, 95% CI 91.9% to 94.0%) than in the Medicine-1st arm (91.3%, 95% CI 89.9% to 92.5%), with IOP-lowering glaucoma surgery required in 0 and 11 patients, respectively. There was a 97% probability of Laser-1st being more cost-effective than Medicine-1st for the NHS, at a willingness to pay for a quality-adjusted life-year of \u00a320,000, with a reduction in ophthalmology costs of \u00a3458 per patient (95% of bootstrap iterations between \u2013\u00a3585 and \u2013\u00a3345).<\/jats:p><\/jats:sec>Limitation<\/jats:title>An unmasked design, although a limitation, was essential to capture any treatment effects on patients\u2019 perception. The EQ-5D-5L questionnaire is a generic tool used in multiple settings and may not have been the most sensitive tool to investigate HRQoL.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Compared with medication, SLT provided a stable, drop-free IOP control to 74.2% of patients for at least 3 years, with a reduced need for surgery, lower cost and comparable HRQoL. Based on the evidence, SLT seems to be the most cost-effective first-line treatment option for OAG and OHT, also providing better clinical outcomes.<\/jats:p><\/jats:sec>Future work<\/jats:title>Longitudinal research into the clinical efficacy of SLT as a first-line treatment will specify the long-term differences of disease progression, treatment intensity and ocular surgery rates between the two pathways.<\/jats:p><\/jats:sec>Trial registration<\/jats:title>Current Controlled Trials ISRCTN32038223.<\/jats:p><\/jats:sec>Funding<\/jats:title>This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment<\/jats:italic>; Vol. 23, No. 31. See the NIHR Journals Library website for further project information.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta23310","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T12:56:44Z","timestamp":1562072204000},"page":"1-102","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":67,"title":["Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT"],"prefix":"10.3310","volume":"23","clinical-trial-number":[{"clinical-trial-number":"isrctn32038223","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-5005","authenticated-orcid":true,"given":"Gus","family":"Gazzard","sequence":"first","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Institute of Ophthalmology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8215-2689","authenticated-orcid":true,"given":"Evgenia","family":"Konstantakopoulou","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Institute of Ophthalmology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-1155","authenticated-orcid":true,"given":"David","family":"Garway-Heath","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Institute of Ophthalmology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-3496","authenticated-orcid":true,"given":"Anurag","family":"Garg","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Institute of Ophthalmology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-670X","authenticated-orcid":true,"given":"Victoria","family":"Vickerstaff","sequence":"additional","affiliation":[{"name":"Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London, London, UK"},{"name":"Research Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Hunter","sequence":"additional","affiliation":[{"name":"Research Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5322-7327","authenticated-orcid":true,"given":"Gareth","family":"Ambler","sequence":"additional","affiliation":[{"name":"Department of Statistical Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-3713","authenticated-orcid":true,"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8723-0148","authenticated-orcid":true,"given":"Richard","family":"Wormald","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Institute of Ophthalmology, University College London, London, UK"},{"name":"London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-8183","authenticated-orcid":true,"given":"Neil","family":"Nathwani","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-7410","authenticated-orcid":true,"given":"Keith","family":"Barton","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Institute of Ophthalmology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-4953","authenticated-orcid":true,"given":"Gary","family":"Rubin","sequence":"additional","affiliation":[{"name":"Institute of Ophthalmology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-3563","authenticated-orcid":true,"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Applied Health Research, Institute of Epidemiology and Health Care, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-5857","authenticated-orcid":true,"given":"Marta","family":"Buszewicz","sequence":"additional","affiliation":[{"name":"Research Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2019,6]]},"reference":[{"key":"key20190627164313398_ref1-bib1","first-page":"771","article-title":"Prevalence and causes of blindness and visual impairment in Mongolia: a survey of populations aged 40 years and older","volume":"72","author":"Baasanhu","year":"1994","journal-title":"Bull World Health Organ"},{"key":"key20190627164313398_ref1-bib2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2458-6-58","article-title":"Leading causes of certification for blindness and partial sight in England & Wales","volume":"6","author":"Bunce","year":"2006","journal-title":"BMC Public Health"},{"key":"key20190627164313398_ref1-bib3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1167\/iovs.06-0886","article-title":"Risk of falls and motor vehicle collisions in glaucoma","volume":"48","author":"Haymes","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20190627164313398_ref1-bib4","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1167\/iovs.07-1609","article-title":"Glaucoma and on-road driving performance","volume":"49","author":"Haymes","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20190627164313398_ref1-bib5","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archopht.1997.01100160617016","article-title":"Visual function and quality of life among patients with glaucoma","volume":"115","author":"Parrish","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/bjo.83.5.546","article-title":"Patients\u2019 perception of visual impairment in glaucoma: a pilot study","volume":"83","author":"Nelson","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/archopht.1997.01100150779014","article-title":"Influence of glaucomatous visual field loss on health-related quality of life","volume":"115","author":"Gutierrez","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00061198-200304000-00009","article-title":"Quality of life in glaucoma and its relationship with visual function","volume":"12","author":"Nelson","year":"2003","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/archopht.122.6.813","article-title":"The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals","volume":"122","author":"Higginbotham","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/archopht.117.5.573","article-title":"The Ocular Hypertension Treatment Study: design and baseline description of the participants","volume":"117","author":"Gordon","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"key":"key20190627164313398_ref1-bib14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ophtha.2003.09.025","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results","volume":"111","author":"Ederer","year":"2004","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib15","volume-title":"NICE: Guidance on Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"key20190627164313398_ref1-bib16","volume-title":"Focus in Ophthalmology \u2013 Glaucoma Management","author":"Royal College of Ophthalmologists"},{"key":"key20190627164313398_ref1-bib17","volume-title":"Review of Clinical Guideline (CG85) \u2013 Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension: Costing Report","author":"National Institute for Health and Care Excellence","year":"2009"},{"key":"key20190627164313398_ref1-bib18","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/bmj.325.7377.1396","article-title":"Beta blockers for glaucoma and excess risk of airways obstruction: population based cohort study","volume":"325","author":"Kirwan","year":"2002","journal-title":"BMJ"},{"key":"key20190627164313398_ref1-bib19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/OPTH.S9716","article-title":"Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications","volume":"4","author":"Fukuchi","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"key20190627164313398_ref1-bib20","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","article-title":"Side effects associated with prostaglandin analog therapy","volume":"53","author":"Alm","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"key20190627164313398_ref1-bib21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1543-5946(03)90003-1","article-title":"Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a Medicare health maintenance organization","volume":"1","author":"Balkrishnan","year":"2003","journal-title":"Am J Geriatr Pharmacother"},{"key":"key20190627164313398_ref1-bib22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ophtha.2007.03.088","article-title":"Glaucoma and mortality","volume":"115","author":"Sharkawi","year":"2008","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3109\/09286586.2011.638743","article-title":"Managing glaucoma in those with co-morbidity: not as easy as it seems","volume":"19","author":"Roughead","year":"2012","journal-title":"Ophthalmic Epidemiol"},{"key":"key20190627164313398_ref1-bib24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"Nordstrom","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"key20190627164313398_ref1-bib25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/01.icu.0000193078.47616.aa","article-title":"Medication adherence in glaucoma: approaches for optimizing patient compliance","volume":"17","author":"Tsai","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"key20190627164313398_ref1-bib26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ophtha.2009.06.024","article-title":"A comprehensive perspective on patient adherence to topical glaucoma therapy","volume":"116","author":"Tsai","year":"2009","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/bjo.2008.151522","article-title":"Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years\u2019 experience","volume":"93","author":"Rahman","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib29","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/bjo.2010.188607","article-title":"Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database","volume":"95","author":"Rahman","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/bjo.77.9.590","article-title":"Adverse effects of topical antiglaucomatous medications on the conjunctiva","volume":"77","author":"Broadway","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/archopht.1994.01090230051020","article-title":"Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/00061198-199504000-00012","article-title":"Topical antiglaucomatous therapy: adverse effects on the conjunctiva and implications for filtration surgery","volume":"4","author":"Broadway","year":"1995","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00061198-200106000-00017","article-title":"Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva","volume":"10","author":"Broadway","year":"2001","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib34","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","article-title":"Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1001\/archophthalmol.2010.85","article-title":"Monocyte modulation of aqueous outflow and recruitment to the trabecular meshwork following selective laser trabeculoplasty","volume":"128","author":"Alvarado","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib36","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/ceo.12281","article-title":"Mechanisms of selective laser trabeculoplasty: a review","volume":"42","author":"Kagan","year":"2014","journal-title":"Clin Experiment Ophthalmol"},{"key":"key20190627164313398_ref1-bib37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00061198-200604000-00009","article-title":"Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma","volume":"15","author":"McIlraith","year":"2006","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib38","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/bjo.2004.052795","article-title":"A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma","volume":"89","author":"Nagar","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4103\/2008-322X.150814","article-title":"Long term efficacy of repeat selective laser trabeculoplasty","volume":"9","author":"Khouri","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"key20190627164313398_ref1-bib40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/0974-9233.134668","article-title":"Repeat selective laser trabeculoplasty can be effective in eyes with initial modest response","volume":"21","author":"Khouri","year":"2014","journal-title":"Middle East Afr J Ophthalmol"},{"key":"key20190627164313398_ref1-bib41","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10792-013-9729-3","article-title":"Repeatability of primary selective laser trabeculoplasty in patients with primary open-angle glaucoma","volume":"33","author":"Avery","year":"2013","journal-title":"Int Ophthalmol"},{"key":"key20190627164313398_ref1-bib42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00061198-200306000-00018","article-title":"Bleb dysesthesia","volume":"12","author":"Barton","year":"2003","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0002-9394(00)00901-6","article-title":"Glaucoma filtering bleb dysesthesia","volume":"131","author":"Budenz","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"key20190627164313398_ref1-bib44","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/bjophthalmol-2017-310902","article-title":"Treatment of Advanced Glaucoma Study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma-study protocol","volume":"102","author":"King","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1017\/S0266462399015299","article-title":"Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom","volume":"15","author":"Kobelt","year":"1999","journal-title":"Int J Technol Assess Health Care"},{"key":"key20190627164313398_ref1-bib46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0008-4182(06)80006-2","article-title":"Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan","volume":"41","author":"Lee","year":"2006","journal-title":"Can J Ophthalmol"},{"key":"key20190627164313398_ref1-bib47","volume-title":"Eye Health Data Summary \u2013 A Review of Published Data in England","author":"Slade","year":"2014"},{"key":"key20190627164313398_ref1-bib48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1001\/archopht.124.1.12","article-title":"A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma","volume":"124","author":"Lee","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib49","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ophtha.2009.01.042","article-title":"Glaucoma: where to now?","volume":"116","author":"Taylor","year":"2009","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1442-9071.2011.02530.x","article-title":"Economic impact of primary open-angle glaucoma in Australia","volume":"39","author":"Dirani","year":"2011","journal-title":"Clin Experiment Ophthalmol"},{"key":"key20190627164313398_ref1-bib51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archophthalmol.2012.355","article-title":"Cost of selective laser trabeculoplasty vs topical medications for glaucoma","volume":"130","author":"Seider","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib52","doi-asserted-by":"publisher","first-page":"e5745","DOI":"10.1097\/MD.0000000000005745","article-title":"Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity","volume":"95","author":"Guedes","year":"2016","journal-title":"Medicine"},{"key":"key20190627164313398_ref1-bib53","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1185\/03007990802379996","article-title":"Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US","volume":"24","author":"Cantor","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"key20190627164313398_ref1-bib54","doi-asserted-by":"publisher","first-page":"CD003919","DOI":"10.1002\/14651858.CD003919.pub2","article-title":"Laser trabeculoplasty for open angle glaucoma","volume":"4","author":"Rolim de Moura","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key20190627164313398_ref1-bib55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/bjophthalmol-2017-310877","article-title":"Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology","volume":"102","author":"Gazzard","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib56","volume-title":"Health-related Quality of Life in Two Treatment Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: An Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty versus Conventional Medical Therapy","author":"National Institute for Health Research"},{"key":"key20190627164313398_ref1-bib57","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40273-018-0650-5","article-title":"Sensitivity analysis for not-at-random missing data in trial-based cost-effectiveness analysis: a tutorial","volume":"36","author":"Leurent","year":"2018","journal-title":"PharmacoEconomics"},{"key":"key20190627164313398_ref1-bib58","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","article-title":"Selective laser trabeculoplasty vs drops for the treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial","volume":"393","author":"Gazzard","year":"2019","journal-title":"Lancet"},{"key":"key20190627164313398_ref1-bib59","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0161-6420(99)90497-9","article-title":"Early Manifest Glaucoma Trial: design and baseline data","volume":"106","author":"Leske","year":"1999","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib60","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"key20190627164313398_ref1-bib61","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/OPX.0b013e3181339f30","article-title":"Developing a preference-based Glaucoma Utility Index using a discrete choice experiment","volume":"84","author":"Burr","year":"2007","journal-title":"Optom Vis Sci"},{"key":"key20190627164313398_ref1-bib62","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/archopht.116.7.861","article-title":"The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms","volume":"116","author":"Lee","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib63","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/fampra\/cmi027","article-title":"A comparison of two methods of collecting economic data in primary care","volume":"22","author":"Patel","year":"2005","journal-title":"Fam Pract"},{"key":"key20190627164313398_ref1-bib64","volume-title":"Terminology and Guidelines for Glaucoma 3rd Edn","author":"European Glaucoma Society","year":"2008"},{"key":"key20190627164313398_ref1-bib65","volume-title":"Primary Open-Angle Glaucoma: Preferred Practice Pattern","author":"American Academy of Ophthalmology","year":"2005"},{"key":"key20190627164313398_ref1-bib66","volume-title":"South East Asia Gluacoma Interest Group: Asia Pacific Glaucoma Guidelines","author":"South East Asia Gluacoma Interest Group (SEAGIG)","year":"2003"},{"key":"key20190627164313398_ref1-bib67","volume-title":"Good Clinical Practice","author":"Medicines and Healthcare products Regulatory Agency (MHRA)","year":"2010"},{"key":"key20190627164313398_ref1-bib68","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1167\/iovs.08-2955","article-title":"The relationship between diurnal variations in intraocular pressure measurements and central corneal thickness and corneal hysteresis","volume":"50","author":"Kotecha","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20190627164313398_ref1-bib69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0008-4182(03)80060-1","article-title":"Canadian perspectives in glaucoma management: setting target intraocular pressure range","volume":"38","author":"Damji","year":"2003","journal-title":"Can J Ophthalmol"},{"key":"key20190627164313398_ref1-bib70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ajo.2005.07.044","article-title":"Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease","volume":"141","author":"Mills","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"key20190627164313398_ref1-bib71","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/ijg.0000000000000218","article-title":"Is myopic optic disc appearance a risk factor for rapid progression in medically treated glaucomatous eyes with confirmed visual field progression?","volume":"25","author":"Lee","year":"2016","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib72","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/bjophthalmol-2017-310870","article-title":"The laser in glaucoma and ocular hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics","volume":"102","author":"Konstantakopoulou","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"41","key":"key20190627164313398_ref1-bib73","doi-asserted-by":"publisher","DOI":"10.3310\/hta11410","article-title":"The clinical effectiveness and cost-effectiveness of screening for open-angle glaucoma: a systematic review and economic evaluation","volume":"11","author":"Burr","year":"2007","journal-title":"Health Technol Assess"},{"key":"key20190627164313398_ref1-bib74","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0008-4182(06)80025-6","article-title":"Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses","volume":"41","author":"Canadian Glaucoma Study Group","year":"2006","journal-title":"Can J Ophthalmol"},{"key":"key20190627164313398_ref1-bib75","volume-title":"Death Registrations Summary Tables \u2013 England and Wales","author":"Office for National Statistics","year":"2016"},{"key":"key20190627164313398_ref1-bib76","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Health and Care Excellence","year":"2008"},{"key":"key20190627164313398_ref1-bib77","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/bjo.2005.067355","article-title":"Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe","volume":"89","author":"Traverso","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib78","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1167\/iovs.08-2457","article-title":"Optic disc progression in glaucoma: comparison of confocal scanning laser tomography to optic disc photographs in a prospective study","volume":"50","author":"Chauhan","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20190627164313398_ref1-bib79","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"key20190627164313398_ref1-bib80","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.ophtha.2013.01.002","article-title":"Development and validation of a predictive model for nonadherence with once-daily glaucoma medications","volume":"120","author":"Chang","year":"2013","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cct.2015.07.016","article-title":"Are multiple primary outcomes analysed appropriately in randomised controlled trials? A review","volume":"45","author":"Vickerstaff","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"key20190627164313398_ref1-bib82","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1167\/iovs.07-0559","article-title":"Evaluation of quality of life and priorities of patients with glaucoma","volume":"49","author":"Aspinall","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20190627164313398_ref1-bib83","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E","article-title":"Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data","volume":"16","author":"Cnaan","year":"1997","journal-title":"Stat Med"},{"key":"key20190627164313398_ref1-bib84","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40273-014-0247-6","article-title":"An educational review of the statistical issues in analysing utility data for cost-utility analysis","volume":"33","author":"Hunter","year":"2015","journal-title":"PharmacoEconomics"},{"key":"key20190627164313398_ref1-bib85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"key":"key20190627164313398_ref1-bib86","volume-title":"Guides to the Methods of Technology Appraisal","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key20190627164313398_ref1-bib87","volume-title":"Unit Costs of Health and Social Care 2017","author":"Curtis","year":"2017"},{"key":"key20190627164313398_ref1-bib88","volume-title":"Methods for the Economic Evaluation of Health Care Programmes: Fourth Edition","author":"Drummond","year":"2015"},{"key":"key20190627164313398_ref1-bib89","volume-title":"British National Formulary (Online)","author":"Joint Formulary Committee"},{"key":"key20190627164313398_ref1-bib90","volume-title":"National Schedule of Reference Costs 2016\u201317","author":"Department of Health and Social Care (DHSC), Finance and Costing Team","year":"2018"},{"key":"key20190627164313398_ref1-bib91","first-page":"200","volume-title":"Measuring Mental Health Needs","author":"Beecham","year":"1992"},{"key":"key20190627164313398_ref1-bib92","doi-asserted-by":"publisher","first-page":"e011121","DOI":"10.1136\/bmjopen-2016-011121","article-title":"Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial","volume":"6","author":"Violato","year":"2016","journal-title":"BMJ Open"},{"key":"key20190627164313398_ref1-bib93","volume-title":"Exploring the Cost of Care at the End of Life","author":"Georghiou","year":"2014"},{"key":"key20190627164313398_ref1-bib94","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","article-title":"Adherence and persistence with glaucoma therapy","volume":"53","author":"Schwartz","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"key20190627164313398_ref1-bib95","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archophthalmol.2011.2727","article-title":"Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma","volume":"130","author":"Stein","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib96","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/bjophthalmol-2012-302525","article-title":"Direct healthcare costs of glaucoma treatment","volume":"97","author":"Rahman","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib97","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1185\/030079906X104687","article-title":"The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries","volume":"22","author":"Holmstrom","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key20190627164313398_ref1-bib98","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1177\/0272989X13478195","article-title":"Accounting for costs, QALYs, and capacity constraints: using discrete-event simulation to evaluate alternative service delivery and organizational scenarios for hospital-based glaucoma services","volume":"33","author":"Crane","year":"2013","journal-title":"Med Decis Making"},{"key":"key20190627164313398_ref1-bib99","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1167\/iovs.12-11549","article-title":"Cost-effectiveness of treating normal tension glaucoma","volume":"54","author":"Li","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20190627164313398_ref1-bib100","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/sj.eye.6702964","article-title":"Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model","volume":"23","author":"Stewart","year":"2009","journal-title":"Eye"},{"key":"key20190627164313398_ref1-bib101","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1755-3768.2011.02318.x","article-title":"The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma","volume":"90","author":"van Gestel","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"key20190627164313398_ref1-bib102","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1186\/s12913-016-1849-9","article-title":"More frequent, more costly? Health economic modelling aspects of monitoring glaucoma patients in England","volume":"16","author":"Boodhna","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"key20190627164313398_ref1-bib103","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/bjophthalmol-2015-306757","article-title":"Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective","volume":"100","author":"Hernandez","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib104","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/jamaophthalmol.2015.44","article-title":"Comparative cost-effectiveness of the baerveldt implant, trabeculectomy with mitomycin, and medical treatment","volume":"133","author":"Kaplan","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"key20190627164313398_ref1-bib105","doi-asserted-by":"publisher","first-page":"e0137913","DOI":"10.1371\/journal.pone.0137913","article-title":"The cost-effectiveness analysis of teleglaucoma screening device","volume":"10","author":"Thomas","year":"2015","journal-title":"PLOS ONE"},{"key":"key20190627164313398_ref1-bib106","doi-asserted-by":"publisher","first-page":"e657","DOI":"10.1097\/IJG.0000000000000313","article-title":"Cost\u2013utility analysis of cataract surgery in advanced glaucoma patients","volume":"25","author":"Xu","year":"2016","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib107","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1167\/iovs.14-14014","article-title":"A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SD-OCT in African American communities","volume":"55","author":"Blumberg","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20190627164313398_ref1-bib108","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/IJG.0b013e31821dac2a","article-title":"Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches","volume":"21","author":"Orme","year":"2012","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib109","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ophtha.2008.12.056","article-title":"The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States","volume":"116","author":"Rein","year":"2009","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib110","first-page":"S240","article-title":"An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension","volume":"8","author":"Stewart","year":"2002","journal-title":"Am J Manag Care"},{"key":"key20190627164313398_ref1-bib111","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1755-3768.2007.00947.x","article-title":"Cost effectiveness and cost utility of an organized screening programme for glaucoma","volume":"85","author":"Vaahtoranta-Lehtonen","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"key20190627164313398_ref1-bib112","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1355819613499748","article-title":"Is it worthwhile to conduct a randomized controlled trial of glaucoma screening in the United Kingdom?","volume":"19","author":"Burr","year":"2014","journal-title":"J Health Serv Res Policy"},{"key":"key20190627164313398_ref1-bib113","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/aos.12328","article-title":"The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension","volume":"92","author":"van Gestel","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"key20190627164313398_ref1-bib114","doi-asserted-by":"publisher","first-page":"CD004399","DOI":"10.1002\/14651858.CD004399.pub3","article-title":"Medical versus surgical interventions for open angle glaucoma","volume":"9","author":"Burr","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"29","key":"key20190627164313398_ref1-bib115","doi-asserted-by":"publisher","DOI":"10.3310\/hta16290","article-title":"Surveillance for ocular hypertension: an evidence synthesis and economic evaluation","volume":"16","author":"Burr","year":"2012","journal-title":"Health Technol Assess"},{"key":"key20190627164313398_ref1-bib116","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1017\/S0266462308080288","article-title":"Economic evaluation of screening for open-angle glaucoma","volume":"24","author":"Hernandez","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"key20190627164313398_ref1-bib117","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/archophthalmol.2010.83","article-title":"Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension","volume":"128","author":"Kymes","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib118","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ajo.2010.01.037","article-title":"The increased cost of medical services for people diagnosed with primary open-angle glaucoma: a decision analytic approach","volume":"150","author":"Kymes","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key20190627164313398_ref1-bib119","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ajo.2006.01.019","article-title":"Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study","volume":"141","author":"Kymes","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"key20190627164313398_ref1-bib120","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/sj.eye.6702637","article-title":"Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist","volume":"22","author":"Peeters","year":"2008","journal-title":"Eye"},{"key":"key20190627164313398_ref1-bib121","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/eye.2010.133","article-title":"The relationship between visual field loss in glaucoma and health-related quality-of-life","volume":"24","author":"van Gestel","year":"2010","journal-title":"Eye"},{"key":"key20190627164313398_ref1-bib122","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","author":"Szende","year":"2014"},{"key":"key20190627164313398_ref1-bib123","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1600-0420.2005.00621.x","article-title":"Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden","volume":"84","author":"Kobelt","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"key20190627164313398_ref1-bib124","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jval.2011.08.002","article-title":"A review of generic preference-based measures of health-related quality of life in visual disorders","volume":"15","author":"Tosh","year":"2012","journal-title":"Value Health"},{"key":"key20190627164313398_ref1-bib125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2018.09.034","article-title":"Are patient self-reported outcome measures sensitive enough to be used as\u2009end\u2009points in clinical trials?: evidence from the United Kingdom Glaucoma Treatment Study","volume":"126","author":"Jones","year":"2019","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib126","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ophtha.2014.08.014","article-title":"Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients","volume":"122","author":"Medeiros","year":"2015","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib127","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/IJG.0b013e3181752c83","article-title":"Assessing quality of life in patients with glaucoma using the Glaucoma Quality of Life-15 (GQL-15) questionnaire","volume":"18","author":"Goldberg","year":"2009","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib128","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/112067210201200406","article-title":"Intraocular pressure response of capsular glaucoma and primary open-angle glaucoma to selective Nd:YAG laser trabeculoplasty: a prospective, comparative clinical trial","volume":"12","author":"Gracner","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"key20190627164313398_ref1-bib129","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/archophthalmol.2011.108","article-title":"Intraocular pressure response to selective laser trabeculoplasty in the first treated eye vs the fellow eye","volume":"129","author":"Shazly","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib130","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2147\/OPTH.S17237","article-title":"Effect of prior cataract surgery on the long-term outcome of selective laser trabeculoplasty","volume":"5","author":"Shazly","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"key20190627164313398_ref1-bib131","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1055\/s-2006-926725","article-title":"Long-term follow-up of selective laser trabeculoplasty in primary open-angle glaucoma","volume":"223","author":"Gracner","year":"2006","journal-title":"Klin Monbl Augenheilkd"},{"key":"key20190627164313398_ref1-bib132","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/archopht.121.7.957","article-title":"Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study","volume":"121","author":"Melamed","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib133","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/IJG.0b013e3182027596","article-title":"Selective laser trabeculoplasty in the treatment of open-angle glaucoma","volume":"21","author":"Koucheki","year":"2012","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib134","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1442-9071.2004.00839.x","article-title":"Five-year follow up of selective laser trabeculoplasty in Chinese eyes","volume":"32","author":"Lai","year":"2004","journal-title":"Clin Experiment Ophthalmol"},{"key":"key20190627164313398_ref1-bib135","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2147\/OPTH.S53490","article-title":"Selective laser trabeculoplasty: current perspectives","volume":"9","author":"Leahy","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"key20190627164313398_ref1-bib136","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","article-title":"Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?","volume":"112","author":"Robin","year":"2005","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib137","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"key20190627164313398_ref1-bib138","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/IJG.0b013e3181752c97","article-title":"A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty (SLT) as a primary therapy in primary open-angle glaucoma and ocular hypertension","volume":"18","author":"Prasad","year":"2009","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib139","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0002-9394(14)76215-4","article-title":"Diurnal intraocular pressure after successful primary laser trabeculoplasty","volume":"112","author":"Els\u00e5s","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"key20190627164313398_ref1-bib140","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0161-6420(83)34479-1","article-title":"Effect of argon laser trabeculoplasty on the glaucomatous diurnal curve","volume":"90","author":"Greenidge","year":"1983","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib141","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1097\/IJG.0000000000000026","article-title":"Comparison of fluctuations of intraocular pressure before and after selective laser trabeculoplasty in normal-tension glaucoma patients","volume":"23","author":"Tojo","year":"2014","journal-title":"J Glaucoma"},{"key":"key20190627164313398_ref1-bib142","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/bjo.2008.148510","article-title":"Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty","volume":"93","author":"Nagar","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib143","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.survophthal.2014.06.006","article-title":"Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma","volume":"60","author":"Wong","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"key20190627164313398_ref1-bib144","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12886-015-0091-2","article-title":"Meta-analysis of selective laser trabeculoplasty versus topical medication in the treatment of open-angle glaucoma","volume":"15","author":"Li","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"key20190627164313398_ref1-bib145","volume-title":"Priorities for Glaucoma Research","author":"The James Lind Alliance","year":"2015"},{"key":"key20190627164313398_ref1-bib146","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib147","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/archophthalmol.2007.77","article-title":"Open-angle glaucoma and mortality: the Barbados Eye Studies","volume":"126","author":"Wu","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"key20190627164313398_ref1-bib148","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ophtha.2007.01.040","article-title":"Cost-effectiveness of treating ocular hypertension","volume":"115","author":"Stewart","year":"2008","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib149","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ophtha.2006.02.062","article-title":"Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study","volume":"113","author":"Lee","year":"2006","journal-title":"Ophthalmology"},{"key":"key20190627164313398_ref1-bib150","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0002-9394(14)72062-8","article-title":"Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage","volume":"122","author":"Quigley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"key20190627164313398_ref1-bib151","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1167\/iovs.13-13006","article-title":"Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime","volume":"55","author":"Saunders","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20190627164313398_ref1-bib152","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/bjophthalmol-2012-301827","article-title":"Practical landmarks for visual field disability in glaucoma","volume":"96","author":"Saunders","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"key20190627164313398_ref1-bib153","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1752-9824.2010.01048.x","article-title":"Non-attendance in chronic disease clinics: a matter of non-compliance?","volume":"2","author":"Patterson","year":"2010","journal-title":"J Nurs Healthc Chronic Illn"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta23310\/hta23310.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2009383","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta23310\/hta23310.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2029560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T14:37:36Z","timestamp":1721486256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta23310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":153,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["10.3310\/hta23310"],"URL":"https:\/\/doi.org\/10.3310\/hta23310","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}